#Kite pharma trial
#Kite pharma series

Then there’s other newer platforms gaining traction, like BeReal, a French social app that launched in 2020. The app was founded by Jack Dorsey’s former boss and aims to be an open-source competitor to Twitter, even as it competes with Dorsey’s very similar product called BlueSky, announced in February. Planetary.Social promises to give users more transparency by letting them view and choose the algorithms that control their feeds, something most networks don’t allow. Roy Bahat, head of Bloomberg Beta, said he saw potential in a company called Planetary.Social, which Bloomberg Beta recently backed. Not surprisingly, Musk’s manic approach to change has some venture capitalists keeping a close eye on competing apps. Eng serves on the board of directors for the Stevenson House. Patel served as Eli Lilly and Company’s senior medical advisor, while Barnes served as a clinical science lead at Acceleron Pharma. Li served as the senior member of technical staff at the Aerospace Corporation.Īristea Therapeutics, a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, welcomed Himanshu Patel, as executive medical director, Jennifer Barnes as senior director, clinical science and Walter Frank Eng as associate director, clinical science. Impulse Space, an in-space transportation services company, tapped Gary Li as manager of business development. Prior to joining, Jensen served as senior vice president at Mott MacDonald. Jensen as senior vice president of project execution and delivery. Pamphile served as general manager at Aser Ventures.Ĭloud-based platform AuditBoard promoted Evan Fitzpatrick from senior vice president to chief product officer.Įnergy Vault, a company developing gravity-based energy storage technology, named E.B. Metaverse platform LAMINA1 hired Géraldine Pamphile as chief business development officer.

#Kite pharma series

Prior to Chamberlain Coffee, Ahern served as the director of brand marketing at Carvana.ĪBC Signature tapped former vice president of series Sydnee Rimes to SVP of series. Gen Z coffee brand Chamberlain Coffee added Liz Ahern as chief marketing officer. Howe previously served as DTx Pharma’s CFO.

Lineage Cell Therapeutics, a clinical-stage biotechnology company developing allogeneic cell therapies appointed Jill Howe as chief financial officer. This milestone has been years in the making.” “Today’s FDA approval brings that hope to more patients by enabling the power of CAR-T cell therapy to be used earlier in the treatment journey. “Kite started with a very bold goal: creating the hope of survival through cell therapy,” Kite CEO Christi Shaw said in a statement. Gilead Sciences acquired Kite for $11.9 billion in 2017. Kite Pharma has focused almost exclusively on CAR-T cell therapies since it was founded in 2009. Culver City-based Appia Bio, meanwhile, emerged from stealth last spring to create off-the-shelf cell therapies that can be delivered quicker and cheaper to patients, and inked a deal with Kite Pharma last August to develop CAR-T cell treatments.

In January, West Hills-based ImmPACT Bio raised $111 million to further its work of reengineering patients’ cells to boost the immune system.

#Kite pharma trial

While most clinical CAR-T cell trials involve patients who are at an advanced stage in their cancer treatments, Yescarta’s clinical trial was filled with patients who used the drug as a second- or third-resort.ĬAR-T cell therapies have taken the oncology world by storm as a promising, potentially less invasive route for treating cancers, with many local biotech firms making moves in the space.

At that point, however, their immune systems may be too weak to effectively utilize the therapeutic. Most CAR-T cell therapies are reserved as a last resort for cancer patients who have exhausted all other options. Yescarta, an intravenous CAR-T cell treatment that aims to bolster the immune system to fight cancer cells, is the first therapeutic of its kind to receive FDA approval for the early treatment of large B-cell lymphoma-a type of non-Hodgkin lymphoma-that has either relapsed or can’t be addressed with other cancer treatments like chemoimmunotherapy. Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a new immunotherapy drug that can be used in the early-stage treatment of certain cancers.